About US
Contact us
-
Did Emflaza's DMD approval expose cracks at the FDA? Lawmakers want to knowAfter lambasting Marathon Pharma for its pricing strategy on a decades-old med recently approved to treat Duchenne muscular dystrophy, Sen. Bernie Sanders and Rep. Elijah Cummings are turning their fi2017/4/7
-
Zostavax patients sue Merck, claiming shingles shot caused injuries and deathMerck & Co. could have a growing Zostavax problem on its hands. After several plaintiffs filed lawsuits claiming the drugmaker’s shingles vaccine caused serious injury and death, attorneys say mor2017/4/7
-
Roche's Herceptin one step closer to biosim battle with Mylan licensing dealMylan and partner Biocon cleared another hurdle with their version of Roche’s breast cancer med Herceptin, one of the biggest biosim targets in the market. To wrap up their patent dispute, Roche will2017/4/6
-
Surprised shareholders target Allergan over generics pricing probeAllergan no longer ownsActavis, having unloaded the generics unit to Teva. That hasn't kept the drugmaker from facing potential fallout from shareholders who say Allergan’s share price has been stung2017/4/6
-
BOTH CRODA’S UNITED STATES SITES RECEIVE EXCiPACT GMPBrussels, 04 April, 2017EXCiPACT asbl is delighted to announce that both Croda Inc. manufacturing sites in the USA have recently beenawarded an EXCiPACT Certificate from SGS, one of EXCIPACT’s interna2017/4/5
-
FMC Corporation Announces Acquisition of Significant Portion of DuPont's Crop Protection Business; Simultaneous Sale of Health and Nutrition to DuPont- FMC will acquire the portion ofDuPont'sCrop Protection business required to be divested by aEuropean Commissionruling related toDuPont'smerger withThe Dow Chemical Company. -DuPontwill acquireFMC2017/4/1
-
Could Sandoz have stalled Mylan's generic Advair? Maybe so, analyst says, citing FDA postNovartis has done its best to stall rivals setting up for the Advair generics party, at least until its Sandoz unit is ready to join. And one analyst says there's a chance it worked. Monday—just one2017/4/1
-
Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparibCall it an early spring surprise for Tesaro. The company’s closely watched ovarian cancer drug niraparib—now dubbed Zejula—wonan FDA nod Monday, months before its scheduled decision date. And not onl2017/3/31
-
Serelaxin's demise ups the stakes on Novartis' latest Entresto-boosting movesNovartis needs Entresto to step up now more than ever. A follow-up heart failure drug, serelaxin, bombed a phase 3 trial last week, and though the Swiss drugmaker did not say it’s giving up on the med2017/3/31
-
Appeals court ruling resurrects 5,000 lawsuits tied to Merck & Co. Fosamax dangersThree years after a federal judge dismissed about 5,000lawsuits by patients claiming Merck & Co.’s osteoporosis drug Fosamax was responsible for their femur fractures, a higher court says Merck wi2017/3/30